What does this research mean for the field?

Partial epigenetic reprogramming can reverse cellular aging phenotypes and restore youthful gene expression profiles, with evidence from preclinical studies showing up to 75% reversal of biological age markers. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.CHALLENGES_CONSENSUS.

What question did this study set out to answer?

The review evaluates the potential of partial epigenetic reprogramming to reverse biological aging while maintaining cell identity.

February 28, 2026Open Access

Partial Epigenetic Reprogramming as a Strategy for Biological Aging Reversal: Preclinical Evidence, Mechanistic Framework, and the Transition to First-in-Human Clinical Trials

View Full Paper

Ask AI

Bookmark

Authors

ZRZen Revista

Discussion

Member takes

Overview

This review uncovers preclinical evidence of epigenetic reprogramming's potential to reverse aging via new therapies, suggesting future advancements in clinical applications.

Key Points

The review evaluates the potential of partial epigenetic reprogramming to reverse biological aging while maintaining cell identity.
Examination of theoretical foundations and experimental evidence
Analysis of preclinical studies using subsets of Shinya Yamanaka factors (OSK)
Review of FDA IND clearance for ER-100 gene therapy
Restoration of youthful gene expression profiles
Reversal of epigenetic clock measurements by up to 75%
Functional rejuvenation in models including vision recovery and enhanced wound healing

Cite This Study

Zen Revista (2026) studied this question.

synapsesocial.com/papers/69a287b00a974eb0d3c03908 https://doi.org/10.5281/zenodo.18792926

View Full Paper

Ask AI

Bookmark

February 28, 2026Open Access

Partial Epigenetic Reprogramming as a Strategy for Biological Aging Reversal: Preclinical Evidence, Mechanistic Framework, and the Transition to First-in-Human Clinical Trials

View Full Paper

Ask AI

Bookmark

Authors

ZRZen Revista

Discussion

Member takes

Overview

This review uncovers preclinical evidence of epigenetic reprogramming's potential to reverse aging via new therapies, suggesting future advancements in clinical applications.

Key Points

The review evaluates the potential of partial epigenetic reprogramming to reverse biological aging while maintaining cell identity.
Examination of theoretical foundations and experimental evidence
Analysis of preclinical studies using subsets of Shinya Yamanaka factors (OSK)
Review of FDA IND clearance for ER-100 gene therapy
Restoration of youthful gene expression profiles
Reversal of epigenetic clock measurements by up to 75%
Functional rejuvenation in models including vision recovery and enhanced wound healing

Cite This Study

Zen Revista (2026) studied this question.

synapsesocial.com/papers/69a287b00a974eb0d3c03908 https://doi.org/10.5281/zenodo.18792926

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark